Welcome to our dedicated page for Oric Pharmaceuticals SEC filings (Ticker: ORIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ORIC Pharmaceuticals, Inc. filings document a Nasdaq-listed clinical-stage oncology company focused on therapeutic resistance in cancer. Its 8-K reports furnish financial results and operational updates, clinical presentation materials for rinzimetostat (ORIC-944) and enozertinib (ORIC-114), and Regulation FD investor presentation slides.
Other disclosures cover ORIC's common stock, shelf registration and at-the-market share sales, prospectus supplement activity, emerging growth company status, and annual meeting proxy matters. The proxy record addresses stockholder voting, board governance, compensation oversight, and equity incentive arrangements, including inducement grants under Nasdaq listing rules.
Oric Pharmaceuticals Chief Medical Officer Pratik S. Multani received new equity awards in the form of stock options and restricted stock units. On January 2, 2026, he was granted stock options covering 214,000 shares of Oric common stock at an exercise price of $8.17 per share. According to the vesting schedule, 25% of these options will vest on January 2, 2027, with the remaining options vesting in equal monthly installments over the following 36 months.
He was also granted 35,500 restricted stock units, each representing a contingent right to receive one share of Oric common stock. One-third of these RSUs will vest on each of December 15, 2026, December 15, 2027, and December 15, 2028, subject to the award terms. All reported holdings are listed as directly owned.
Oric Pharmaceuticals, Inc. insider equity activity shows its Chief Medical Officer reporting routine stock transactions. On December 15, 2025, the officer acquired 29,333 shares of Oric common stock at $0 through the vesting and settlement of restricted stock units (RSUs). The filing states that each RSU represents a right to receive one share of common stock.
On December 16, 2025, the officer sold 10,720 shares of common stock at a weighted average price of $9.0605 per share to cover tax withholding obligations tied to the RSU vesting, described as not a discretionary sale. After these transactions, the officer beneficially owned 68,149 shares of Oric common stock, including 2,771 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Oric Pharmaceuticals, Inc. reported insider equity activity by its Chief Financial Officer. On 12/15/2025, the CFO acquired 29,333 shares of common stock at an exercise price of $0 through the settlement of restricted stock units (RSUs), increasing direct beneficial ownership to 78,868 shares.
On 12/16/2025, the CFO sold 10,720 shares of common stock at a weighted average price of $9.0604 per share, leaving 68,148 shares owned directly. The sale was made solely to cover tax withholding obligations related to RSU vesting. The holdings include 1,218 shares acquired under the company’s 2020 Employee Stock Purchase Plan, and remaining RSUs continue to vest in equal annual installments each December 15 from 2025 through 2027.
Oric Pharmaceuticals, Inc. reported an equity transaction by its President and CEO, who is also a director. On December 15, 2025, the executive acquired 83,666 shares of common stock at $0 upon the vesting and settlement of restricted stock units (RSUs). On December 16, 2025, 33,374 shares of common stock were sold at a weighted average price of $9.06 to cover tax withholding obligations related to the RSU vesting, described as a non-discretionary sale. Following these transactions, the executive beneficially owned 581,711 shares of Oric common stock directly, with additional RSUs remaining subject to vesting over future dates.
ORIC Pharmaceuticals, Inc. provided a program update on its enozertinib (ORIC-114) candidate, presenting recently announced data from its Phase 1b trial. The update was delivered through a presentation included as Exhibit 99.1, giving stakeholders access to the detailed clinical information the company shared on this program.
ORIC Pharmaceuticals furnished an 8-K under Item 7.01 to provide updated ORIC-944 data slides for use in future investor presentations. The materials are included as Exhibit 99.1 and incorporated by reference in the report.
The company states the information in Item 7.01 and Item 9.01 (including Exhibit 99.1) is furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated into other filings except by specific reference.
ORIC Pharmaceuticals filed its Q3 2025 10-Q, reporting a net loss of $32.6 million for the quarter and $99.0 million for the nine months ended September 30, 2025. Operating expenses were $36.7 million in Q3, driven by research and development of $28.8 million and general and administrative of $7.9 million.
Liquidity strengthened: cash, cash equivalents and investments were $413.0 million as of September 30, 2025, supported by financing. During Q3 2025, the company raised $108.7 million net via its ATM through the sale of 10,930,032 shares at a weighted average price of $10.10. In May 2025, it completed a private placement for $125.0 million gross, including pre-funded warrants. Management believes current resources fund the plan into the second half of 2028.
ORIC announced a strategic pipeline prioritization on August 12, 2025, focusing on ORIC-944 and enozertinib, with an approximately 20% workforce reduction and a one-time charge of about $1.9 million. As of November 5, 2025, shares outstanding were 97,389,279. The company highlighted ORIC-944 dose optimization progress and expects an enozertinib data update in the fourth quarter of 2025.
ORIC Pharmaceuticals furnished an update on its financials by issuing a press release covering results for the fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The information under Item 2.02 and Item 9.01 (including Exhibit 99.1) is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated by reference into other filings unless specifically referenced. The report was signed by Dominic Piscitelli, Chief Financial Officer.
Oric Pharmaceuticals insider transactions by CFO Dominic Piscitelli show a simultaneous option exercise and sale on 10/06/2025. The filing reports exercise of 11,000 stock options at an exercise price of $4.36 per share, resulting in immediate acquisition of 11,000 common shares. Those 11,000 shares were sold under a Rule 10b5-1 plan at a weighted average price of $14.5199 per share, completing sales in the $14.50–$14.53 range and leaving the reporting person with 48,317 shares outstanding directly. After the transactions, the reporting person holds 196,500 shares subject to outstanding options. The sale was executed pursuant to a trading plan adopted on 06/24/2025.
Oric Pharmaceuticals director and CEO Chacko Jacob reported the sale of 37,461 shares of ORIC common stock on 10/06/2025. The filing shows the shares were sold under a Rule 10b5-1 trading plan adopted on 06/21/2025 at a weighted average price of $12.32 (range $12.07–$12.59). After the reported sale, the reporting person beneficially owned 531,419 shares directly; the filing separately discloses 178,667 RSUs and 3,378,000 stock options previously reported on Table II and not included in that total. The Form 4 was signed by an attorney-in-fact on 10/08/2025.